Small intestine cancer
MONDO:0000956A primary or metastatic malignant neoplasm involving the small intestine.
Also known as: cancer of small intestine, malignant neoplasm of small bowel, malignant neoplasm of small intestine, malignant neoplasm of the small bowel, malignant neoplasm of the small intestine, malignant small bowel neoplasm, malignant small bowel tumor, malignant small bowel tumour
2963 clinical trials for this condition and its sub-types, 8 tagged with Small intestine cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Small intestine cancer
-
Small intestine carcinoma 19 trials · 105 incl. sub-types
3 sub-types
- Carcinoma of duodenum 21 trials · 75 incl. sub-types Sub-types →
- Small intestine adenocarcinoma 18 trials · 60 incl. sub-types Sub-types →
- Squamous cell carcinoma of the small intestine 1 trial Sub-types →
-
Duodenum cancer 15 trials · 82 incl. sub-types
2 sub-types
- Carcinoma of duodenum 21 trials · 75 incl. sub-types Sub-types →
- Ampulla of vater cancer 5 trials · 69 incl. sub-types Sub-types →
-
Small intestine lymphoma 3 trials
4 sub-types
-
Small intestinal sarcoma 0 trials · 1 incl. sub-types
2 sub-types
- Small intestine leiomyosarcoma 1 trial
- Small intestinal fibrosarcoma 0 trials
-
Ileum cancer 0 trials
1 sub-type
- Meckel diverticulum cancer 0 trials
-
Jejunal cancer 0 trials
1 sub-type
- Jejunal adenocarcinoma 0 trials
Most studied deeper sub-types
-
New hope for hard-to-treat cancers: targeted combo shows promise
Disease control OngoingThis study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the com…
Phase 1/2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC